Skip to main content
Premium Trial:

Request an Annual Quote

Affy Registers Uptick in Q2 Revenue, Narrowed Loss

SAN FRANCISCO, July 25 - Affymetrix yesterday reported a bump up in revenue, decreased losses, and a slight increase in R&D for the second quarter.


Revenue for the period ended June 30 rose to $70.7 million, including $5.6 million from wafers sales from Perlegen Sciences, compared to total revenue of $49.5 million for the second quarter of 2001, the company said.


R&D spending rose to $17.3 million from $16.5 million for the same period a year ago, and net loss decreased to $1.6 million, or $.03 per share, in the second quarter 2002 compared to $9.1 million, or $.16 per share, in the year-ago period.


Affy also reported $134.8 million in cash and cash equivalents at the end on June 2002.


Click here for more information.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.